Physician profile
John C Storch
NPI 1275577975
$1,076.53
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $196 · 2020: $89.18 · 2021: $368 · 2022: $423.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $385.61 | 2021-2022 | |
| Pfizer INC. | $203.35 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $138.73 | 2019-2022 | |
| Amgen INC. | $86.10 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $66.21 | 2019-2022 | |
| Novo Nordisk INC | $45.47 | 2022 | |
| Esperion Therapeutics, INC. | $38.74 | 2020-2021 | |
| Microtransponder, INC. | $27.97 | 2022 | |
| Shield Therapeutics INC | $24.67 | 2022 | |
| Eisai INC. | $22.68 | 2020 | |
| Novartis Pharmaceuticals Corporation | $21.72 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.28 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Storch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.